Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2006-02-13
2011-11-29
Staples, Mark (Department: 1637)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
Reexamination Certificate
active
08067175
ABSTRACT:
Polymerase chain reaction primers and methods directed to detecting the EGFR mutant C→T at the position corresponding to base 2369 of EGFR cDNA. The invention provides a PCR primer that hybridizes under suitable PCR conditions to a polynucleotide sequence 5′ in each respective strand to a mutation of an EGFR gene that encodes a substitution of threonine by methionine at position 790 of the EGFR polypeptide. The invention also provides a PCR primer hybridizes to a sequence that includes a mutant T at the position corresponding to base 2369 of EGFR cDNA but not to a second EGFR polynucleotide containing a wild type C. The invention provides several methods and kits for detecting a mutant epidermal growth factor receptor (EGFR) gene in a sample comprising probing the sample with a means for selectively detecting a nucleotide sequence comprising a mutant T at the position corresponding to base 2369 of EGFR cDNA, and identifying that the base at said position is T. These methods and kits are also useful to predict resistance to the therapeutic effects of gefitinib or erlotinib in a subject suffering from or suspected of having a cancer.
REFERENCES:
patent: WO 2005/118876 (2005-12-01), None
Natale et al., Quantitative gene expression in non-small cell lung cancer from paraffin-embedded tissue specimens: Predicting response to gefitinib, an EGFR kinase inhibitor, Proc Am Soc Clin Oncol 22: 2003 (abstr 763).
Genbank, Acession No. T39469.1, ya06c09.r1 Stratagene placenta (#937225)Homo sapienscDNA Image:60688 5—similar to similar to SP:EGFR—Human P00533 Epidermal Growth Factor Receptor Precursor ,, m sequence, updated 1995, pp. 1-2, retrieved 2010.
Khatua et al., Overexpression of the EGFR/FKBP12/HIF-2—Pathway Identified in Childhood Astrocytomas by Angiogenesis Gene Profiling, Cancer Research 63, 1865-1870, Apr. 15, 2003 pp. 1865-1870.
Buck et al., Research Report, Design Strategies and Performance of Custom DNA Sequencing Primers BioTechniques 27:528-536 (Sep. 1999).
Paez et al. Supplementary Material pp. 1-17 for Science 304, 1497 (2004); Clinical Response to Gefitinib Therapy EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy.
Neff et al., Web-based primer design for single nucleotide polymorphism analysis, Trends in Genetics vol. 18 No. 12 Dec. 2002, pp. 613-615.
Wu DY et al., “Allele-Specific Enzymatic Amplification of Beta-Globin Genomic DNA for Diagnosis of Sickle Cell Anemia”, Proc. Natl. Acad. Sci. USA, Apr. 1, 1989, pp. 2757-2760, vol. 86.
Rieger T et al., “Detection of Small Amounts of Mutated Mitochondrial DNA by Allele-Specific PCR (AS-PCR)”, Meth. Mol. Cell. Biol., Jan. 1, 1993, pp. 121-127, vol. 4.
Beaulieu M et al., “A Novel Method for Molecular Haplotyping Combining a Improved AS-PCR Technique with Base Specific Cleavage of Nucleic Acid Analyzed by Mass Spectrometry”, [title of item unknown], putative date provided by EPO: Nov. 1, 2003, p. 441, putative vol. provided by EPO: vol. 73, No. 5.
Al-Ali HK, et al. (2004) High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J 5: 55-60.
Blencke S, et al. (2003) Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J Biol Chem 278: 15435-15440.
Blencke S, et al. (2004) Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem Biol 11: 691-701.
Bozyczko-Coyne D, et al. (1993) A rapid fluorometric assay to measure neuronal survival in vitro. J Neuroscience Meth 50: 205-216.
Chen LL, et al. (2004) A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 64: 5913-5919.
Cools J, et al. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348: 1201-1214.
Daub H, et al. (2004) Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov 3: 1001-1010.
Deininger M, et al. (2004) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood: prepubl online Dec. 23, 2004 DOI 10.1182/blood-2004-08-3097.
Gorre ME, et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880.
Gorre ME, and Sawyers CL (2002) Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol 9: 303-307.
Huang SF, et al. (2004) High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10: 8195-8203.
Kosaka T, et al. (2004) Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res 64: 8919-8923.
Kreuzer KA, et al. (2003) Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique. Ann Hematol 82: 284-289.
Krug LM, et al. (2001) Randomized phase II trial of trastuzumab (tras) plus either weekly docetaxel (doc) or paclitaxel (pac) in previously untreated advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20: 1328.
Lynch et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
O'Hare T, et al. (2004) Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: Implications for CML. Blood 104: 2532-2539.
Paez JG, et al. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
Pao W, et al. (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101: 13306-13311.
Pao W, et al. (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Medicine 2: e17.
Sawyers C (2004) Targeted cancer therapy. Nature 432: 294-297.
Shah NP, et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117-125.
Shah NP, et al. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399-401.
Shigematsu H, et al. (2004) Clinical and biological features of epidermal growth factor receptor mutations in lung cancers. J Natl Cancer Inst 97: 339-346.
Sordella R, et al. (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167.
Stamos J, et al. (2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 277: 46265-46272.
Tamborini E, et al. (2004) A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127: 294-299.
Tracy S, et al. (2004) Gefitinib induces apoptosis in the EGFRL858R non-small cell lung cancer cell line H3255. Cancer Res 64: 7241-7244.
Wood ER, et al. (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64: 6652-6659.
Blencke S et al., “Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors”, J. Biol. Chem., Apr. 25, 2003, pp. 15435-15440, vol. 278, No. 17.
Blencke S et al., “Characterization of a conserved structural
Miller Vincent
Pao William
Politi Katerina
Varmus Harold
Larson & Anderson LLC
Memorial Sloan-Kettering Cancer Center
Staples Mark
LandOfFree
Methods and compositions for detecting a drug resistant EGFR... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for detecting a drug resistant EGFR..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for detecting a drug resistant EGFR... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4278738